Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine in Dilated Cardiomyopathy
NCT06250257Phase 3Recruiting
- Sponsor
- Jimma University
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bromocriptine in dilated cardiomyopathy (DCM) (2 arms), sponsored by Jimma University. Primary endpoints: Left ventricular function improvement at 9 months, Improvement of cardiac biomarkers (N-terminal Pro BNP) at 9 months and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
bromocriptine
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT06250257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250257.